Tang Capital Management LLC Acquires New Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Tang Capital Management LLC acquired a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 50,000 shares of the company's stock, valued at approximately $2,677,000. Tang Capital Management LLC owned about 0.10% of Janux Therapeutics as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the business. Lester Murray Antman dba SimplyRich boosted its holdings in Janux Therapeutics by 205.3% in the fourth quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company's stock valued at $1,301,000 after acquiring an additional 16,351 shares in the last quarter. abrdn plc purchased a new stake in shares of Janux Therapeutics in the 4th quarter worth about $3,430,000. Barclays PLC lifted its position in shares of Janux Therapeutics by 496.5% in the 3rd quarter. Barclays PLC now owns 174,061 shares of the company's stock worth $7,907,000 after purchasing an additional 144,883 shares during the period. Legal & General Group Plc lifted its position in shares of Janux Therapeutics by 45.3% in the 4th quarter. Legal & General Group Plc now owns 34,540 shares of the company's stock worth $1,849,000 after purchasing an additional 10,776 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Janux Therapeutics by 1.6% in the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after purchasing an additional 599 shares during the period. 75.39% of the stock is currently owned by institutional investors.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total transaction of $106,755.99. Following the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $2,630,912.17. This trade represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. bought 341,742 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were acquired at an average price of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the purchase, the director now owns 9,658,988 shares in the company, valued at approximately $295,951,392.32. The trade was a 3.67% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 10,001 shares of company stock valued at $313,964. 29.40% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on JANX shares. Wedbush reaffirmed an "outperform" rating and issued a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, Scotiabank dropped their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $95.25.

Janux Therapeutics Price Performance

JANX stock traded down $0.63 on Wednesday, reaching $24.77. 748,634 shares of the company traded hands, compared to its average volume of 868,767. The firm has a fifty day simple moving average of $28.38 and a 200-day simple moving average of $40.22. The company has a market cap of $1.47 billion, a P/E ratio of -21.17 and a beta of 3.24. Janux Therapeutics, Inc. has a one year low of $22.48 and a one year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.